ANG Lifesciences India Ltd

Director Reappointment

• Type of change: Reappointment of Independent Director.
• Name and designation: Mrs. Chetna, Independent Director.
• Effective: Oct 12, 2026 to Oct 11, 2031 (five-year term).
• Reason: Reappointment.
• Profile: corporate law, securities, SEBI compliance; LLB, CS, MBA Finance.
• Relationships: No relationship with other Directors or KMP.
• Regulatory status: Not debarred from Director by SEBI or authorities.
• Board impact: No stated change to board/committee composition.

AGM Details

• AGM held 30 Sep 2026 at 12:00 PM via VC/OAVM at the registered office (deemed venue).

Key Resolutions

• Adopt standalone financial statements for year ended 31 March 2026 with directors'/auditors' reports.
• Adopt consolidated financial statements for year ended 31 March 2026 with directors'/auditors' reports.
• Re-appoint Rohit Mittal as Director by rotation.
• Ratify Cost Auditor remuneration for FY 2026-27.
• Re-appoint Chetna as Independent Director.

Voting Status

• Voting outcomes not disclosed in this document; Scrutinizer report to be disseminated separately.

Director Changes

• Rohit Mittal to be re-appointed as Director.
• Chetna to continue as Independent Director.

Auditor Details

• Cost Auditor remuneration for FY 2026-27 ratified.

ANG Lifesciences India Ltd trading window closed from 01 October 2026 till the end of 48 hours after declaration of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026

Financial performance

• Standalone revenue from operations: 9,233.11 lakhs.
• Standalone PBT: -519.09 lakhs.
• Standalone PAT: -472.64 lakhs.
• Standalone EPS: -3.52 per share.
• Consolidated revenue from operations: 9,289.28 lakhs.
• Consolidated PBT: -1,301.07 lakhs.
• Consolidated PAT: -1,108.49 lakhs.
• Consolidated EPS: -8.43 per share.
• Dividend declared: Nil.

Capital structure & liquidity

• Standalone debt: 6,496.98 lakhs.
• Standalone net debt: 6,139.43 lakhs.
• Standalone gearing: 0.99.
• Consolidated debt: 7,782.04 lakhs.
• Consolidated net debt: 7,374.00 lakhs.
• Consolidated gearing: 1.39.

Governance & board matters

• Independent Director Chetna to be re-appointed for 2026-2031.
• Cost Auditor remuneration Rs 80,000; ratified for 2026-27.
• Board size six; three independent directors.
• Rohit Mittal to be re-appointed as Director.
• Statutory auditor Khurana Sharma & Co appointed for five years.

Subsidiaries & group structure

• Wholly owned subsidiary: Mansa Print & Publishers Limited.
• Subsidiary turnover 486.21; PBT -781.98; PAT -635.84 (Standalone basis).
• Subsidiary equity ownership: 100% by ANG Lifesciences India Limited.

Related party transactions

• Related party transactions were at arm's length and in the ordinary course.
• Details disclosed in Annexure-2; policy on RPT available on company website.

Audit flags & regulatory matters

• GST ITC reversal liability of 6.65 lakhs; not regularized on GST portal.
• Four litigations against the company totaling Rs 99.81 lakhs.
• Non-compliance observations: SDD reporting and certain statutory payments noted.

Outlook and risks

• Management expects a positive, improving outlook despite macro headwinds.

AGM Details

• AGM scheduled for 30 September 2026 at 12:00 PM via VC/OAVM.

Book Closure Details

• Book closure from 24.09.2026 to 30.09.2026 (inclusive) for AGM.
• Record date for voting entitlement: 23.09.2026.
• Purpose: 20th Annual General Meeting.

AGM Details

• Date and day: 30 September 2026 (Wednesday).
• Time: 12:00 PM.
• Mode: VC/OAVM per MCA/SEBI guidelines.
• This is the company's 20th AGM.

Appointments/Resignations

• Appointed Cost Auditor M/s Shreya Sahu & Associates for FY 2026-27 (FRN 101389).
• Appointed Scrutinizer: M/s Anii Negi & Company, Practicing Company Secretary, for evoting.
• Reappointment of Rohit Mittal, retire-by-rotation; to be placed before shareholders at the 20th AGM.
• Reappointment of Mrs. Chetna (DIN: 08981045) as Independent Director for 5-year term (2026–2031), subject to approval.

AGM / Book Closure

• AGM fixed for 30 September 2026 at 12:00 PM via VC/OAVM; Notice approved.
• Book Closure from 24 September to 30 September 2026; record date 23 September 2026.

Board / Financial Reporting

• FY2025-26 Board’s Report with annexures approved.

Standalone results

• Revenue from operations at ₹1,395.79 lakhs; Total revenue ₹1,415.05 lakhs.
• PBT before tax at ₹-451.12 lakhs; PAT at ₹-341.76 lakhs.
• EPS (basic/diluted) at ₹-2.59 for quarter ended 30 June 2026.

Consolidated results

• Revenue from operations at ₹1,529.77 lakhs; Total revenue ₹1,540.54 lakhs.
• PBT before tax at ₹-557.95 lakhs; PAT at ₹-422.65 lakhs.
• Auditors expressed unmodified opinion on standalone and consolidated results.

Meeting Details

• Date: Friday, 14 August 2026; Time: 05:00 P.M.; Venue: Darbara Complex, SCO-113, Amritsar.

Key Agenda Items

• Consider and approve Standalone and Consolidated Un-Audited financial results for quarter ended 30 June 2026.

Other Notes

• Trading window closed from 01 July 2026 to 48 hours after results made public on 14 August 2026.